Table 2.

The association of study chair responses on trial design factors and accrual sufficiency status

	Overall, % (n=110)	By trial accrual status, %
		Sufficient (n=75)	Insufficient (n=35)	p-value
Time elapsed from trial concept introduction to trial activation
≤12 mos	43	45	37
>12 - ≤ 24 mos	40	41	37
>24 - ≤ 36 mos	11	7	20
> 36 mos	6	7	6	0.11
Perception of eligibility criteria
Appropriate	86	88	83
Overly restrictive	13	11	17
Overly permissive	1	1	0	0.54
	Therapeutic trials only, % (n= 86)	By trial accrual status, %
		Sufficient (n= 60)	Insufficient (n= 26)	p-value
Use of placebo, observation, or non-treatment control arm reported
Yes	31	27	42
No	69	73	58	0.15
Best descriptor of treatments compared in trial
Novel therapy vs established therapy	65	70	54
Two or more novel therapies	8	7	11
Head-to-head comparison of well-established therapies	27	23	35	0.36